### Journal of Advanced Biomedical and Pharmaceutical Sciences

Journal Homepage: http://jabps.journals.ekb.eg



# Two smart spectrophotometric methods for simultaneous determination of Lisinopril and Hydrochlorothiazide in binary mixtures

## Fatma F. Mohammed<sup>1</sup>, Khalid M. Badr El-Din<sup>1,2\*</sup>, Sayed M. Derayea<sup>1</sup>

<sup>1</sup> Department of Analytical Chemistry, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt

<sup>2</sup> Department of Analytical Chemistry, Faculty of Pharmacy, Deraya University, 61111 New Minia, Egypt

Received: December 19, 2018; revised: January 12, 2019; accepted: January 15, 2019

#### Abstract

Two new, simple, fast and sensitive spectrophotometric methods were developed for analysis of binary mixtures of Lisinopril (LIS) and hydrochlorothiazide (HCT). These methods were absorptivity factor method and ratio subtraction method. In the first method, calculations were made using the absorbance of the mixtures at 211 nm where LIS absorptivity is half HCT absorptivity. On the other hand, the second method was based on obtaining the original spectrum of LIS from the zero order spectrum of the binary mixture then determining the concentration of LIS from its linear regression equation. HCT concentration in both methods was determined from the absorbance at 270 nm where a lack of interference of LIS occurs. The methods were validated according to ICH and applied successfully on different ratios of laboratory mixtures and on pharmaceutical tablets with excellent accuracy and precision.

#### Key words

Spectrophotometric, Lisinopril, Hydrochlorothiazide, Absorptivity factor, Ratio subtraction

#### 1. Introduction

LIS (Figure 1), the third ACE inhibitor approved for use in the United States, is the lysine analogue of enalaprilat; unlike ENA, LIS itself is active. In vitro, LIS is a slightly more potent ACE inhibitor than is enalaprilat. They are both used for treatment of heart failure and hypertension [1]. Diuretic drugs e.g. HCT (Figure 1) and angiotensin converting enzyme (ACE) inhibitors e.g. LIS are amongst the major therapeutic advances of modern medicine due to their dramatic influence in the treatment of congestive cardiac failure and arterial hypertension. Diuretics achieve hypotension by eliminating salt and water, thus reducing blood volume. The renin-angiotensin system is immediately stimulated as a reflex response in order to conserve blood volume. When ACE inhibitors are used at the same time, activation of the renin-angiotensin system is prevented, enhancing the effect of both therapies and decreasing their side effects as lower doses are needed [2, 3].

LIS was previously analyzed by titrimetric [4], spectrophotometric [5-14], Spectrofluorimetric [15-19], chromatographic [20-38], electrophoretic [39, 40] and electrochemical methods [4, 41, 42].

Mixtures of LIS and HCT were analyzed simultaneously by spectrophotometric [43-45], chromatographic [21, 22, 29, 46-48], electrophoretic [39] and electrochemical methods [49].

However, chromatographic, electrophoretic and electrochemical methods require expensive instruments and large volumes of solvents, and limited number of spectrophotometric methods was available in literature to for simultaneous determination of both drugs including multivariate [43], ratio spectra derivative, derivative and Vierordt's spectrophotometric methods [44, 45]. So this work aimed to develop new spectrophotometric methods that have the advantages of being rapid, more sensitive, cheap and simple to perform.



Figure 1: Chemical structures of LIS and HCT.

## 2. Theories of the proposed methods 2.1. The absorptivity factor method

The absorptivity factor is the ratio between the two absorptivities  $(a_x, a_y)$  of two mixed substances X & Y at intersection point with the same absorbance value. This point is called the absorptivity factor point  $(\lambda_F)$ . If Y can be determined using well-known spectrophotometric methods, the absorptivity factor method is applied for the determination the concentration of X. The final equation that is applied in this method is:

$$A_m = a_y (FC_x + C_y) \quad (1$$

Where,  $A_m$  are the absorbance of X, Y and their mixture at the absorptivity factor point ( $\lambda_F$ ), F is the absorptivity factor,  $a_x$  and

 $a_{\rm y}$  are the absorptivities of X and Y respectively.  $C_x$  and  $C_y$  are the concentrations of X and Y respectively.

From equation (1) we can calculate the total concentration (FC<sub>x</sub> + C<sub>y</sub>) via the regression equation representing the linear relationship between the absorbance of Y and its corresponding concentration at the absorptivity factor point. The concentration of X can be determined after subtraction of concentration of Y and multiplication by the inverse of F. [50, 51]

#### 2.2. Ratio subtraction method

When two drugs X and Y were combined and have overlapping spectra but one drug (Y) has an extended part in its zero order spectrum where no interference from drug (X) exists. Then drug X can be determined using ratio subtraction technique by dividing the zero order spectrum of the mixture by the zero order spectrum of a certain concentration of Y named as the divisor (Y'). The obtained constant is subtracted then the resulting spectra is multiplied by the divisor (Y') to isolate the original spectrum of X that can be determined by applying the linear regression equation of its calibration at its  $\lambda_{max}$ . On the other hand drug (Y) can be determined by applying the linear regression equation of its calibration at  $\lambda_{max}$  of the extended curve [50, 52].

#### 3. Experimental 3.1. Apparatus

The instrument used throughout the work was Spectronic Genesis 2PC UV/visible (Milton Roy Co, USA) connected to IBM computer, that is uploaded with winspec software (version 1.22), and using 1cm quartz cuvette.

# 3.2. Materials3.2.1. Pure authentic samples

LIS dihydrate powder (purity = 98.9 %) was generously provided by Sedico Co for pharmaceuticals (Cairo, Egypt) while HCT powder (purity = 98.2 %) was generously supplied by Amoun Co for pharmaceuticals (Cairo, Egypt). No further purification was done on the obtained powders.

#### 3.2.2. Solvent

Methanol (analytical grade) was purchased from El Nasr chemical Co (Cairo, Egypt) and it was used as the main solvent for dissolution and dilution for all analyzed drugs.

#### 3.2.3. Commercial tablets

Sinopril Co<sup>®</sup> tablets (Global Napi pharmaceuticals, Egypt) that were labeled to contain 20 mg LIS + 12.5 mg HCT were analyzed in this work (batch no. E23305).

#### 3.3. Standard solutions

LIS and HCT powders were accurately weighed and dissolved separately in methanol to prepare a stock standard solution of concentration 100.0  $\mu$ g mL<sup>-1</sup>. Working solutions were prepared

by further dilution with methanol in a series of 10-mL volumetric flasks to give final concentration ranges of 1.0 - 30.0 and 2.5 -  $30.0 \ \mu g \ mL^{-1}$  in order to construct calibration curve for LIS and HCT, respectively.

#### **3.4. General methods of analysis 3.4.1. The absorptivity factor method**

Zero order spectrum of LIS (10.0  $\mu$ g mL<sup>-1</sup>) and HCT (5.0  $\mu$ g mL<sup>-1</sup>) were recorded. There were two points of intersections at 204 and 211 nm (Two absorptivity points). Wavelength of 211 nm was chosen for analysis because at this wavelength accurate results and better % recoveries were obtained. Two calibration curves were constructed for HCT by measuring the absorbance at both 270 nm and 211 nm to obtain two linear regression equations.

In order to analyze mixture containing LIS and HCT, the mixture is scanned and the absorbance values at both 211 nm (absorptivity factor point) and 270 nm are recorded. The concentration of HCT is determined through the linear regression equation at 270 nm where no interference from LIS occurs. Then LIS concentration is determined by subtracting HCT concentration from the value obtained using the linear regression equation at 211 nm and finally multiplying the result by 2.

#### 3.4.2. Ratio subtraction method

Five different concentrations of LIS in the range of  $5.0 - 30.0 \ \mu g \ mL^{-1}$  were scanned and calibration curve was constructed by measuring the absorbance at 210 nm (its  $\lambda_{max}$ ) relative to the concentration. The divisor (Y') was the zero order spectrum of 5.0  $\mu g \ mL^{-1}$  solution of HCT. To perform the analysis on a binary mixture, the spectrum of the mixture is divided by the divisor. A constant value appears in the region where extension of HCT spectrum occurred (260-280 nm). Subtraction of this constant from the spectrum and then multiplication of the obtained spectrum by the divisor (Y') isolates the original spectrum of LIS. Determination of LIS concentration at 210 nm while HCT concentration is determined from the linear regression equation of its calibration at 270 nm by measuring the absorbance of the binary mixture at 270 nm.

#### 3.5. Analysis of laboratory prepared mixtures

Accurate aliquots of either LIS or HCT were transferred into 10-mL volumetric flasks to prepare mixtures containing different ratios including 1:1, 1:2, 2:1, 1:3, 3:1, 2:3 and 3:2 then the solutions were completed to the mark with methanol. The final solutions were analyzed according to the general methods.

#### 3.6. Analysis of pharmaceutical tablets

Ten tablets of Sinopril Co<sup>®</sup> tablets were accurately weighed, finely minced and mixed carefully. An accurately weighed portions of the powdered tablets equivalent to 10 mg LIS + 6.25 mg HCT are mixed in adequate portion of methanol, sonicated

for 10 minutes then filtration is done into 100-mL volumetric flask and the volume was completed to the mark with methanol to form stock solutions of 100.0  $\mu$ g mL<sup>-1</sup> of LIS + 62.5  $\mu$ g mL<sup>-1</sup> HCT. Different aliquots were taken and diluted to prepare working solutions and the general procedure was followed.

#### 4. Results and discussion

The purpose of the present work is to develop new, sensitive, simple and fast analytical methods for simultaneous determination of LIS and HCT in their bulk powders and pharmaceutical formulations with high degree of accuracy and precision and without the need for preliminary separation of each drug individually such as extraction or filtration procedures. As well, to construct a statistical comparison between the ability of the proposed methods to determine both drugs in their pure form, laboratory prepared mixtures and in their pharmaceutical formulations. A serious spectral overlap was observed when the mixture of LIS and HCT in methanol was scanned in the wavelength region of 200 - 300 nm which prevent the direct determination of LIS (Figure 2). Therefore different methods were applied for attaining high separation and quantitative estimation of both drugs with no significant interference.



**Figure 2:** Zero order spectrum of LIS (10 µg mL<sup>-1</sup>) and HCT (10 µg mL<sup>-1</sup>) showing overlapped spectra.

#### 4.1. Absorptivity factor point

The absorption spectra of LIS and HCT in the ratio (1:1); recorded in methanol show a severe spectral overlap in the wavelength region of 200 – 300 nm (**Figure 2**) without any point of intersection. But if the concentration of LIS is doubled (20 µg mL<sup>-1</sup>), two intersection points will appear at 204 and 211 nm (**Figure 3**). At the absorptivity factor point  $a_x/a_y = C_y/C_x = F$ , then the absorptivity factor point (F) = 1/2.

HCT concentration was determined from the linear regression equation at 270 nm without interference (**Figure 4**). The wavelength 211 nm was chosen in the present work because it had given more accurate results. The linear regression equation obtained from the calibration of HCT at 211 nm (**Figure 4**) gave a value equals ( $FC_x + C_y$ ). The concentration of LIS was obtained by subtracting HCT concentration  $(C_y)$  and multiplying the result by 2 (the inverse of F).



Figure 3: Zero order spectrum of LIS ( $20 \ \mu g \ mL^{-1}$ ) and HCT ( $10 \ \mu g \ mL^{-1}$ ) showing two intersection points at 204 and 211 nm.



Figure 4: Calibration curve of HCT at 270 nm and at 211 nm (Absorptivity factor point).

#### 4.2. Ratio subtraction method

The mixture of LIS and HCT which have overlapping spectra could be resolved by using spectra ratio subtraction method. The spectrum of the mixture was recorded in the region of 200 -300 nm and divided by the spectrum of a known concentration of HCT (5  $\mu g~m L^{\text{-1}})$  as a divisor. A new curve was obtained representing  $\frac{LIS}{HCT}$  + constant (Figure 5). The constant can be obtained from the plateau in the region of 260 -300 nm. If the constant is subtracted from the curve in Figure 5, the ratio spectrum of LIS/HCT will be given. The sole spectrum of LIS in the mixture could be obtained through multiplying the ratio spectrum by the divisor spectrum (5 µg/mL HCT)). This gave the original zero order spectra of LIS in the mixture, which can be used for direct determination of LIS at 210 nm (Figure 6). The concentration of LIS could be calculated from the corresponding regression equation (obtained by plotting the absorbance values of the zero order curves of LIS at 210 nm against the corresponding drug concentrations) (Figure 7).



Figure 5: The division spectra of three analysed binary mixtures of LIS: HCT after division by the divisor (Y') showing plateau in the extended region (260-280).



Figure 6: The Final spectra of three analysed binary mixtures of LIS: HCT after constant subtraction and multiplication by the divisor (Y') showing the original spectrum of LIS.



Figure 7: Calibration curve of LIS at 210 nm ( $\lambda$ max).

#### 4.3. Validation of the proposed methods

ICH recommendations (53) were adopted to assess validation of the proposed method. Linearity, accuracy, precision, specificity, LOD and LOQ were evaluated.

#### 4.3.1. Linearity

**Method I:** Two calibration curves were constructed for HCT at both 211 (absorptivity point) and 270 nm and statistical parameters were calculated (**Table 1**). LOD and LOQ values were found to be 0.297 and 0.90  $\mu$ g mL<sup>-1</sup> at 270 nm while at 211 nm they were found to be 0.790 and 2.40  $\mu$ g mL<sup>-1</sup>, respectively. **Method II:** LIS working solutions were analysed in the concentration ranges of 5.0-30.0  $\mu$ g mL<sup>-1</sup> and calibration curve was constructed from the absorbance values at 210 nm (Table 1). LOD and LOQ values were found to be 1.517 and 4.596  $\mu$ g mL<sup>-1</sup>, respectively.

#### 4.3.2. Accuracy

Accuracy of the proposed methods was evaluated by applying the proposed methods for determination of different laboratory prepared mixtures of LIS and HCT. The concentration of each drug was calculated from the corresponding regression equations. The obtained % recoveries indicate suitable accuracy of the proposed methods (**Table 2**).

Standard addition method was also performed to check the accuracy of the methods. It was applied for analysis of commercial tablets by addition of different amounts of standard LIS or HCT to certain concentration of the extracted tablet solution. The results showed excellent % recoveries with low % RSD (**Table 3**).

#### 4.3.3. Precision

Repetitive analysis of three different laboratory prepared mixtures was performed three successive days in order to evaluate intra- and inter-day precision of the proposed methods. % RSD lower than 2 % were obtained that proved that the proposed methods were precise (**Table 4**).

#### 4.3.4. Specificity

The proposed methods determined successfully LIS and HCT simultaneously without interference from each other (**Table 2**). Also they were applied for their determination in tablets where no interferences from tablet excipients occurred (**Table 5**). This proves the proposed methods specificity for the studied drugs.

#### 4.4. Application on analysis of commercial tablets

The proposed spectrophotometric methods were utilized for the determination of LIS and HCT in their combined pharmaceutical formulation Sinopril Co<sup>®</sup> tablets and the results were present in table 5, the same dosage form was analyzed by the reported method [45]. The spectra of the extracted tablet solutions showed no interferences from tablet excipients that proves the proposed methods' selectivity and specificity (**Figure 8**). The good % recoveries prove the suitable accuracy of the proposed methods for the routine determination of these drugs in their combined dosage form. Also comparison to a reported method [45] was done by repetitive analysis of certain tablet solution of LIS five times with both the proposed and the

Table 1: Statistical parameters for the calibration of HCT at 211 and 270 nm and LIS at 210 nm.

Parameter	HCT	HCT at 211 nm (Absorptivity	LIS
	at 270 nm	point)	at 210 nm
Linear range (µg mL <sup>-1</sup> )	1.0 - 20.0	2.5 - 20.0	5.0-30.0
Slope	0.0642	0.0543	0.0307
Standard deviation of slope (S <sub>b</sub> )	0.0004	0.0009	0.0008
Intercept	0.0194	0.0634	0.0145
Standard deviation of the intercept (S <sub>a</sub> )	0.0058	0.0131	0.0141
Correlation Coefficient*	0.9999	0.9995	0.9990
Standard deviation of residuals (S <sub>y,x</sub> )	0.0104	0.0108	0.0149
LOD ( $\mu g m L^{-1}$ )	0.297	0.790	1.517
$LOQ (\mu g m L^{-1})$	0.90	2.40	4.59

Table 2: Determination of LIS and HCT concentration in laboratory mixtures by the two proposed methods

		% Recovery "						
Mix Ratio —	НСТ	LIS						
	Katio —	(at 270 nm in both methods)	Method I	Method II				
			(at absorptivity point 211 nm)	(at $\lambda_{max}$ 210 nm)				
1	1:1	101.56	101.32	99.07				
2	1:2	102.00	101.67	97.67				
3	2:1	101.56	98.098	100.18				
4	1:3	100.83	99.82	102.34				
5	3:1	99.69	97.72	102.06				
6	2:3	101.46	100.72	101.35				
7	3:2	100.94	97.66	99.96				
N	Iean	101.15	99.57	100.38				
	SD	0.76	1.74	1.68				

a the value is the mean of three determinations.

 Table 3: Standard addition method for the determination of LIS and HCT in Sinopril Co<sup>®</sup> tablets (20 mg LIS + 12.5 mg HCT) by addition of standard LIS or HCT

Amount m	taken (μg L <sup>-1</sup> )	Amount added (µg mL <sup>-1</sup> )	Fo	Found <sup>a</sup> (µg mL <sup>-1</sup> )		0	% Recovery <sup>a</sup>		
	T TO	HCT	HCT LIS		HCT	LIS			
LIS	пст	LIS	M 1,2	M 1	M 2	M 1,2	M 1	M 2	
10	6.25	5	6.250	14.860	15.11	100.00	99.07	100.75	
10	6.25	10	6.359	20.479	19.84	101.75	102.39	99.21	
10	6.25	15	6.265	25.481	24.79	100.25	101.93	99.16	
Mean						100.667	101.13	99.70	
SD						0.946	1.79	0.90	
LIS	HCT	HCT							
5	3.125	2.5	5.62	5.12	4.84	99.91	102.19	96.86	
5	3.125	5	8.07	5.01	4.91	99.32	100.14	98.18	
5	3.125	7.5	10.51	5.06	4.95	98.89	101.29	98.90	
Mean						99.37	101.21	97.98	
SD						0.51	1.03	1.03	

a the value is the mean of three determinations,  $M_1$  and  $M_2$  are Method I (absorptivity factor method) and Method II (Ratio subtraction method) respectively.

Table 4: Intra- and inter- day precision for the analysis of LIS and HCT in three laboratory mixtures by the proposed methods.

Concentrati	on level	% Recovery ± RSD					
$(\mu g m L^{-1})$		Intra-day	precision	Inter-day precision			
LIS	HCT	LIS	HCT	LIS	НСТ		
Absorptivity facto	r point method						
10	12.5	100.24±1.86	101.63±1.44	99.14±1.57	$101.32 \pm 1.04$		
5	10	99.69±1.19	$100.59 \pm 1.82$	100.39±1.19	101.31±0.78		
10	5	102.12±0.65	100.72±0.97	99.87±1.25	100.68±1.95		
Ratio subtraction	method						
10	12.5	100.93±0.65	102.42±0.99	100.36±1.26	99.32±1.95		
5	10	97.67±1.17	$100.83 \pm 1.85$	$97.50 \pm 1.17$	99.64±0.78		
10	5	98.54±1.83	$100.26 \pm 1.42$	101.97±1.59	102.53±1.07		

<sup>a</sup> The value is the mean of three determinations.

Table 5: Determination of LIS and HCT	` in Sinopril Co®	<sup>9</sup> tablets and comparison	with reported method.
---------------------------------------	-------------------	-------------------------------------	-----------------------

Conc. taken (µg mL <sup>-1</sup> )		% Recovery <sup>a</sup> ± SD					
			<b>Proposed methods</b>	Reported	Reported method <sup>45</sup>		
	-	$M_1$	$M_2$	M 1,2	-		
LIS	HCT	LIS	LIS	HCT	LIS	HCT	
10	6.25	101.03±1.78	101.23±1.21	99.75±1.88	102.71±0.88	99.33±1.24	
t- value <sup>b</sup>		1.901	2.216	0.415			
F- value		4.103	1.921	2.277			

a the value is the average of five measurements for both the proposed and reported methods.

b Tabulated values at 95% confidence limit are t = 2.306, F = 6.338.



Figure 8: The spectrum of extracted tablet solution containing 5  $\mu$ g mL<sup>-1</sup>LIS + 3.125  $\mu$ g mL<sup>-1</sup>HCT.

reported methods (Table 5). t- and F- values were calculated and was found to be lower than the tabulated indicating that there is no significant differences between both the proposed methods and the reported method.

#### 5. Conclusion

It could be concluded that the proposed methods of analysis new, rapid, simple, sensitive methods represent for simultaneulsy determine the studied drugs in their binary mixtures. The proposed methods have several advantages over the previously reported methods as they are faster and cheaper than chromatographic, electrophoretic and electrochemical methods that require expensive and sophisticated instruments. In addition, They are more simple and cover wider concentration ranges than the reported multivariate spectrophotometric method [43] that needs special mathematical program. Furthermore, the proposed methods are more sensitive than the reported ratio spectra derivative, derivative and Vierordt's spectrophotometric methods [45]. The methods were successfully validated showing high degree of accuracy and precision.

#### References

- [1] Laurence L.Brunton JS, Keith S. Parker. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed 2006.
- [2] Lant AF. Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions—parallels and contrasts. *British Journal of Clinical Pharmacology*. 1987;23(Suppl 1):27S-41S.
- [3] Strube G, Strube G. Combination therapy with ACE inhibitors. ACE Inhibitors in Hypertension: *Springer*; 1992. p. 97-8.
- [4] Olalowo AW, Adegbolagun OM, Bamiro OA. Simple potentiometry and phenolphthalein-based titrimetric methods of analysis for Lisinopril tablets. *African Journal of Pharmacy and Pharmacology*. 2015;9(6):165-72.
- [5] Ali AAA, Elbashir AA. A new spectrophotometric method for the determination of cardiovascular drugs in dosage forms. *American Academic & Scholarly Research Journal*. 2013;5(1):106.
- [6] Elbashir A. A new spectrophotometric method for the determination of cardiovascular drugs in dosage forms. 2016.
- [7] Jamakhandi C, Javali C, Disouza J, Chougule U, Mullani A. Spectrophotometric determination of lisinopril dosage form by condensation reaction. *Int J Pharm Pharm Sci.* 2011;3(2):185-7.
- [8] Nagaraja P, Hrestha AK, Shivakumar A, Al-Tayar NGS. Molybdate Assisted Ninhydrin Based Sensitive Analytical System for the Estimation of Drugs Containing Amine Group. *Journal of Food & Drug Analysis*. 2011;19(1):85-93.

[9] Nasir I, Musa A, Abdullahi M, Garba M. Spectrophotometric determination of lisinopril in three simulated physiological fluids. *Journal of Pharmaceutical and Allied Sciences*. 2017;14(4):2638-45.

[10] Naveed S. Analytical Determination of Lisinopril Using UV Spectrophotometer and HPLC: An Overview. *Mod Chem appl.* 2014;2(137):2.
[11] Paraskevas G, Atta-Politou J, Koupparis M. Spectrophotometric determination of lisinopril in tablets using 1-fluoro-2, 4-dinitrobenzene reagent.

*Journal of pharmaceutical and biomedical analysis*. 2002;29(5):865-72. [12] Shama SA, Amin AS, Omara H. Spectrophotometry Microdetermination of

Some Antihypertensive Drugs in Pure Form and In Pharmaceutical Formulations. *Journal of the Chilean Chemical Society*. 2011;56(1):566-70. [13] Vieriu M, Tantaru G, Apostu M, Panainte AD, Agoroaei L, Uncu L, et al.

A New Spectrometric Method for Quantitative Determination through Molecular Absorption of Lisinopril. *REVISTA DE CHIMIE*. 2015;66(10):1563-6.

[14] Zaheer Z, Khan S, Sadeque M, Baig MS, Sangshetti J. Development and validation of UV spectrophotometric estimation of lisinopril dihydrate in bulk and tablet dosage form using area under curve method. *Journal of Innovations in Applied Pharmaceutical Science*. 2016;1(2):12-6.

[15] Derayea SM, Badr El-Din KM, Mohammed FF. Selective spectrofluorimetric method for determination of Lisinopril in pharmaceutical preparations and in presence of hydrochlorothiazide: Application to content uniformity testing. *Luminescence*. 2017;32(8):1482-7.

[16] Derayea SM, El-din KMB, Mohammed FF. An innovative validated spectrofluorimetric method for determination of Lisinopril in presence of hydrochlorothiazide; application to content uniformity testing. Spectrochimica Acta Part A: *Molecular and Biomolecular Spectroscopy*. 2018;188:318-23.

[17] Jamakhandi C, Javali C, Kumar S, Kumar S, DS SK. New Fluorimetric Method of Determination for Lisinopril Dosage Forms. *Inter J Pharm Sci Drug Res.* 2010;2(3):182-87.

[18] Jamkhandi C, Javali C, Kumar S, Kadadevar D. New Fluorimetric Method Development for Lisinopril by Condensation reaction. *Inter J Pharm Pharm Sci.* 2010;2(4):209-11.

[19] Zacharis CK, Tzanavaras PD, Themelis DG, Theodoridis GA, Economou A, Rigas PG. Rapid spectrofluorimetric determination of lisinopril in pharmaceutical tablets using sequential injection analysis. *Analytical and bioanalytical chemistry*. 2004;379(5-6):759-63.

[20] Arayne MS, Sultana N, Tabassum A, Ali SN, Naveed S. Simultaneous LC determination of rosuvastatin, lisinopril, captopril, and enalapril in API, pharmaceutical dosage formulations, and human serum. *Medicinal Chemistry Research*. 2012;21(12):4542-8.

[21] Elsebaei F, Zhu Y. Fast gradient high performance liquid chromatography method with UV detection for simultaneous determination of seven angiotensin converting enzyme inhibitors together with hydrochlorothiazide in pharmaceutical dosage forms and spiked human plasma and urine. *Talanta*. 2011;85(1):123-9.

[22] Fawzi Elsebaeia YZ. Fast gradient high performance liquid chromatography method with UV detection for simultaneous determination of seven angiotensin converting enzyme inhibitors together with hydrochlorothiazide in pharmaceutical dosage forms and spiked human plasma and urine. *Talanta*. 2011;85:123-9.

[23] Goud NS, Achaiah G, Sivaramakrishna V, Mayuri P. Development and validation of RP-LC method for Lisinopril Dihydrate in bulk and its pharmaceutical formulations. *International Journal of PharmTech Research*. 2015;8(3):448-52.

[24] Kumar V, Shah RP, Singh S. LC and LC–MS methods for the investigation of polypills for the treatment of cardiovascular diseases: Part 1. Separation of active components and classification of their interaction/degradation products. *Journal of pharmaceutical and biomedical analysis.* 2008;47(3):508-15.

[25] Latha Y, Sankar DG. A Novel RP-HPLC Method for Determination of Lisinopril (LP) in Pure and Pharmaceutical Formulation. *Asian Journal of Research in Chemistry*. 2015;8(1):27-9.

[26] Liu YX, Shou D, Chen ML, Chen ZD, Zhang PM, Zhu Y. Determination of lisinopril using anion exchange chromatography with integrated pulsed amperometric detection. *Chinese Chemical Letters*. 2012;23(3):335-8.

[27] Maslarska V, Tencheva J. Development of Analytical Method for Determination of Lisinopril Tablets Using RP-HPLC Method. Int J Pharma Bio Sci. 2013;4(4):163-67.

[28] Odovic JV, Markovic BD, Injac RD, Vladimirov SM, Karljikovic-Rajic KD. Correlation between ultra-high performance liquid chromatography–tandem mass spectrometry and reversed-phase thin-layer chromatography hydrophobicity data for evaluation of angiotensin-converting enzyme inhibitors absorption. *Journal of Chromatography A*. 2012;1258:94-100.

[29] Pandya JJ, Sanyal M, Shrivastav PS. Simultaneous densitometric analysis of amlodipine, hydrochlorothiazide, lisinopril, and valsartan by HPTLC in pharmaceutical formulations and human plasma. *Journal of Liquid Chromatography & Related Technologies*. 2017:1-12.

[30] Rao NM, Gowrisankar D. Stability-indicating HPLC Method for Simultaneous Determination of Atenolol, Aspirin, Lisinopril and Simvastatin in Bulk and Tablets. *Indian Journal of Pharmaceutical Sciences*. 2016;78(2):217-23.

[31] Rastkari N, Ahmadkhaniha R. Development and validation of a high-performance liquid chromatography method for determination of lisinopril

in human plasma by magnetic solid-phase extraction and pre-column derivatization. *Biomedical Chromatography*. 2017:1-10.

[32] Sana A, Naveed S, Qamar F, Shakeel S. Simultaneous determination of ACE inhibitors and dexibuprofen in active pharmaceutical ingredient, formulations and human serum by RP-HPLC. *Pak J Pharm Sci.* 2017;30(2):635-9.

[33] Şenkardeş S, Özaydın T, Uğurlu T, Küçükgüzel ŞG. Development and validation of a reversed-phase HPLC method for the determination of lisinopril and gliclazide in pharmaceuticals. *Marmara Pharmaceutical Journal*. 2017;21(2):338-44.

[34] Shafi N, Siddiqui FA, Sultana N, Arayne MS. Concurrent Determination of Diltiazem, Lisinopril, Captopril, and Enalapril in Dosage Formulations and in Human Serum by Liquid Chromatographic Technique. *Journal of Liquid Chromatography & Related Technologies*. 2015;38(15):1466-73.

[35] Stoimenova TB, Piponski M, Serafimovska GT, Stefova M. Development and validation of a fast, simple, cost-effective and robust HPLC method for lisinopril determination in solid pharmaceutical dosage forms. *Macedonian Journal of Chemistry and Chemical Engineering*. 2017;36(2):201-9.

[36] Sultana N, Naveed S, Arayne M. Direct determination of four ACEinhibitors lisinopril, enalapril, captopril and fosinopril in pharmaceuticals and serum by HPLC. *J Chromat Separation Techniq*, 2013;4(179.5):1-5.

[37] Yu D-R, Yang G-F, Xiao W-L, Wang J, Liu Q-B. Determination of related substances in lisinopril and amlodipine tablets by HPLC. *Journal of Hainan Medical University*. 2016;22(11):9-12.

[38] Zaheer Z, Khan S, Sadeque M, Hundekari G, Zainuddin R. Development and validation for determination of lisinopril dihydrate in bulk drug and formulation using RP-HPLC method. *Journal of Innovations in Applied Pharmaceutical Science*. 2016;1(2):17-21.

[39] Hillaert S, De Grauwe K, Van den Bossche W. Simultaneous determination of hydrochlorothiazide and several inhibitors of angiotensin-converting enzyme by capillary electrophoresis. *Journal of Chromatography A.* 2001;924(1):439-49.

[40] Hillaert S, Van den Bossche W. The quantitative determination of several inhibitors of the angiotensin-converting enzyme by CE. *Journal of pharmaceutical and biomedical analysis*. 2001;25(5):775-83.

[41] Hasanzadeh M, Pournaghi-Azar MH, Shadjou N, Jouyban A. Determination of lisinopril using  $\beta$ -cyclodextrin/graphene oxide-SO3H modified glassy carbon electrode. *Journal of Applied Electrochemistry*. 2014;44(7):821-30.

[42] Razak OA, Belal S, Bedair M, Barakat N, Haggag R. Spectrophotometric and polarographic determination of enalapril and lisinopril using 2, 4-dinitrofluorobenzene. *Journal of pharmaceutical and biomedical analysis.* 2003;31(4):701-11.

[43] Dinç S, Asçi B, Bozdogan AE. Spectrophotometric multicomponent resolution of a tablet formulation containing lisinopril and hydrochlorothiazide by multivariate calibration methods. *Asian Journal of Chemistry*. 2013;25(2):999.

[44] El-Gindy A, Ashour A, Abdel-Fattah L, Shabana MM. Spectrophotometric and HPTLC-densitometric determination of lisinopril and hydrochlorothiazide in binary mixtures. *Journal of pharmaceutical and biomedical analysis.* 2001;25(5):923-31.

[45] Erk N. Comparative Study of the Ratio Spectra Derivative Spectrophotometry, Derivative Spectrophotometry and Vierordt's Method Appued to the Analysis of Lisinopril and Hydrochlorothiazide in Tablets. *Spectroscopy letters*. 1998;31(3):633-45.

[46] Dawud ER, Shakya AK. HPLC-PDA analysis of ACE-inhibitors, hydrochlorothiazide and indapamide utilizing design of experiments. *Arabian Journal of Chemistry*. 2014:1-11.

[47] Nagaraju PG, Bilal A, Siddhartha V. Validated RP-HPLC method for simultaneous estimation of lisinopril and hydrochlorothiazide in combined dosage forms. *International Journal of Chemistry and Pharmaceutical Sciences*. 2014;2(2):635-41.

[48] Shah JV, Shah PA, Shah PV, Sanyal M, Shrivastav PS. Fast and sensitive LC–MS/MS method for the simultaneous determination of lisinopril and hydrochlorothiazide in human plasma. *Journal of Pharmaceutical Analysis*. 2016:163-9.

[49] Valezi CF, Eisele APP, Sartori ER. Versatility of a carbon paste electrode coupled to differential pulse voltammetry for determination of lisinopril with its associations (hydrochlorothiazide and amlodipine). Analytical Methods. 2017;9(31):4599-608.

[50] Lotfy H, Lotfy HM, Saleh SS. Recent development in ultraviolet spectrophotometry through the last decade (2006–2016). *Future*. 2013;1:1.

[51] Samir A, Salem H, Abdelkawy M. New developed spectrophotometric method for simultaneous determination of salmeterol xinafoate and fluticasone propionate in bulk powder and Seritide® diskus inhalation. Bulletin of Faculty of Pharmacy, Cairo University. 2012;50(2):121-6.

[52] El-Bardicy MG, Lotfy HM, El-Sayed MA, El-Tarras MF. Smart stabilityindicating spectrophotometric methods for determination of binary mixtures without prior separation. *Journal of AOAC International*. 2008;91(2):299-310. [53] Validation of Analytical procedures: methodology International Conferenc on Harmonization (ICH) of Technical Requirements for the Registration Pharmaceuticals for Human Use (1996).